Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
<<<
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More